

Supplementary table 2. Comparison of demographics and baseline clinical characteristics between participants with and without complete 12 months follow-up.

	Participants with complete 12 months follow-up (n=75)	participants with missing 12 months follow-up (n=5)
Age – yr	50 ± 14.7	39 ± 15.2
Sex – no. (%)		
Male	22 (29.3%)	1 (20%)
Female	53 (70.7%)	4 (80%)
BMI – kg/m ²	26.3 ± 5.8	23.6 ± 9.4
Previous treatment – no. (%)		
Prokinetic only	22 (29.3%)	2 (40%)
Prokinetic and botulinum toxin injection	27 (36%)	1 (20%)
Prokinetic and transpyloric stenting	14 (18.7%)	2 (40%)
Prokinetic, botulinum toxin injection, and transpyloric stenting	12 (16%)	0 (0%)
Etiology – no. (%)		
Idiopathic	31 (41.3%)	2 (40%)
Diabetes	17 (22.7%)	2 (40%)
Post-surgical	27 (36%)	1 (20%)
Median disease duration (25 th -7 th percentiles) – months	46.7 ± 42.7	66.4 ± 79.2
Average GCSI score at baseline	2.8 ± 1.1	3.5 ± 0.5
GCSI nausea/vomiting score at baseline	2.5 ± 1.4	2.8 ± 1.2
GCSI fullness/early satiety score at baseline	3.3 ± 1.3	4.1 ± 1
GCSI bloating subscale score at baseline	2.6 ± 1.5	3.4 ± 1.1
Gastric retention percent at 4 hours before the G-POEM	37.1 ± 23.4	38.4 ± 10.9

* Plus–minus values are means ± SD.

G-POEM, Gastric per-oral endoscopic myotomy; BMI, body mass index. GCSI, gastroparesis cardinal symptom index.